Get the Stockscreener App
20.10
0.91%
-0.2617
Immunovant Inc stock is traded at $20.10, with a volume of 943.57K.
It is down -0.91% in the last 24 hours and down -18.12% over the past month.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
See More
Previous Close:
$20.36
Open:
$20.36
24h Volume:
943.57K
Relative Volume:
0.92
Market Cap:
$3.46B
Revenue:
-
Net Income/Loss:
$-323.01M
P/E Ratio:
-9.0533
EPS:
-2.22
Net Cash Flow:
$-272.30M
1W Performance:
-7.20%
1M Performance:
-18.12%
6M Performance:
-25.22%
1Y Performance:
-42.75%
1-Day Range:
$19.86
$21.07
1-Week Range:
$19.86
$23.11
52-Week Range:
$19.86
$39.55
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
20.10 | 3.46B | 0 | -323.01M | -272.30M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.55 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.60 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.70 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.77 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Immunovant (NASDAQ:IMVT) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus - MSN
Immunovant (NASDAQ:IMVT) Shares Down 5% After Earnings Miss - MarketBeat
IMVT’s Market Whiplash: -17.80% YTD Decline, -17.34% Plunge in 30 Days - The InvestChronicle
Immunovant, Inc. (NASDAQ:IMVT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Immunovant (NASDAQ:IMVT) Stock Price Down 5% on Disappointing Earnings - Defense World
Immunovant Reports Progress Amid Increased R&D Costs - TipRanks
Immunovant (NASDAQ:IMVT) Sets New 1-Year LowHere's What Happened - MarketBeat
Immunovant's Fiscal Q3 Loss Widens -February 06, 2025 at 07:40 am EST - Marketscreener.com
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 - The Manila Times
ForexTV | Small Business Resources - ForexTV.com
Immunovant's Massive $825M War Chest Fuels Race for Breakthrough Autoimmune Treatments - StockTitan
Investor’s Toolkit: Key Ratios for Assessing Immunovant Inc (IMVT)’s Performance - The Dwinnex
Immunovant Inc (IMVT) may enjoy gains as insiders got busy in the recent days - Knox Daily
Prepare Yourself for Liftoff: Immunovant Inc (IMVT) - SETE News
Immunovant Enters Oversold Territory (IMVT) - Nasdaq
Immunovant (IMVT) Projected to Post Earnings on Monday - MarketBeat
Immunovant (NASDAQ:IMVT) Upgraded at Cantor Fitzgerald - Defense World
Immunovant (NASDAQ:IMVT) Raised to Strong-Buy at Cantor Fitzgerald - MarketBeat
Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025 - Insider Monkey
12 Stocks That Will Double in 2025 - Insider Monkey
Immunovant registers shares for selling stockholders - MSN
Immunovant's chief medical officer Michael Geffner sells $62,678 in stock - MSN
Immunovant CTO Jay Stout sells $51,780 in stock - MSN
Immunovant stock hits 52-week low at $22.39 amid market challenges - MSN
Immunovant (NASDAQ:IMVT) Reaches New 12-Month Low on Insider Selling - Defense World
Immunovant stock hits 52-week low at $22.39 amid market challenges By Investing.com - Investing.com South Africa
Immunovant (NASDAQ:IMVT) Sets New 52-Week Low Following Insider Selling - MarketBeat
Immunovant (NASDAQ:IMVT) vs. Genfit (NASDAQ:GNFT) Head to Head Analysis - Defense World
Immunovant registers shares for selling stockholders By Investing.com - Investing.com Australia
Insider Selling: Immunovant, Inc. (NASDAQ:IMVT) Insider Sells 2,657 Shares of Stock - MarketBeat
Jay S. Stout Sells 2,195 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock - MarketBeat
Immunovant's chief medical officer Michael Geffner sells $62,678 in stock By Investing.com - Investing.com Australia
Immunovant CTO Jay Stout sells $51,780 in stock By Investing.com - Investing.com South Africa
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - The Malaysian Reserve
Guggenheim raises Immunovant stock target to $46, maintains Buy By Investing.com - Investing.com Canada
Cantor Fitzgerald Estimates Immunovant FY2026 Earnings - MarketBeat
Guggenheim raises Immunovant stock target to $46, maintains Buy - MSN
Immunovant's chief medical officer sells $56,782 in stock - MSN
Immunovant CFO Eva Renee Barnett sells $54,756 in stock - MSN
Immunovant CEO Peter Salzmann sells $208,899 in stock - MSN
Peter Salzmann Sells 8,767 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $54,761.34 in Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $56,786.89 in Stock - MarketBeat
Immunovant CEO Peter Salzmann sells $208,899 in stock By Investing.com - Investing.com Canada
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Geffner Michael | Chief Medical Officer |
Jan 22 '25 |
Sale |
23.59 |
2,657 |
62,679 |
132,314 |
| Macias William L. | Chief Medical Officer |
Jan 15 '25 |
Sale |
23.83 |
2,383 |
56,782 |
359,408 |
| Barnett Eva Renee | Chief Financial Officer |
Jan 15 '25 |
Sale |
23.83 |
2,298 |
54,757 |
324,766 |
| Salzmann Peter | Chief Executive Officer |
Jan 15 '25 |
Sale |
23.83 |
8,767 |
208,900 |
964,225 |
| Roivant Sciences Ltd. | Director |
Jan 13 '25 |
Buy |
20.00 |
16,845,010 |
336,900,200 |
96,650,341 |
| Barnett Eva Renee | Chief Financial Officer |
Jan 08 '25 |
Sale |
24.10 |
4,105 |
98,930 |
327,064 |
| Salzmann Peter | Chief Executive Officer |
Jan 08 '25 |
Sale |
24.10 |
5,105 |
123,030 |
972,992 |
| Pande Atul | Director |
Dec 02 '24 |
Sale |
28.54 |
7,750 |
221,185 |
86,663 |
| Hughes Douglas J. | Director |
Dec 02 '24 |
Sale |
28.54 |
5,425 |
154,830 |
119,585 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):